Paper8306418
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.
van Tellingen O and 6 others. Cancer Chemother Pharmacol, 1994. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. Papers, record 8306418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8306418
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Vinblastine | Major topic |
| Animals | |
| Chromatography, High Pressure Liquid | |
| Male | |
| Mice | |
| Mice, Inbred Strains | |
| Tissue Distribution |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 329987 | Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). | Cancer Treat Rev | 1977 | https://conductscience.org/library/papers/329987 | PubMed |
| 2 | 1524896 | Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts. | Eur J Cancer | 1992 | https://conductscience.org/library/papers/1524896 | PubMed |
| 3 | 1822176 | Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. | J Pharm Biomed Anal | 1991 | https://conductscience.org/library/papers/1822176 | PubMed |
| 4 | 5743691 | Historical background of Vinca alkaloid research and areas of future interest. | Cancer Chemother Rep | 1968 | https://conductscience.org/library/papers/5743691 | PubMed |
| 5 | 1618962 | Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection. | J Chromatogr | 1992 | https://conductscience.org/library/papers/1618962 | PubMed |
| 6 | 3898995 | Vinca-23-oyl amino acid derivatives: as new anticancer agents (review). | Anticancer Res | 1985 | https://conductscience.org/library/papers/3898995 | PubMed |
| 7 | 2015595 | Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363. | Cancer Res | 1991 | https://conductscience.org/library/papers/2015595 | PubMed |
| 8 | 13719013 | Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. | Cancer Res | 1960 | https://conductscience.org/library/papers/13719013 | PubMed |
| 9 | 6359081 | Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. | Pharmacotherapy | 1983 | https://conductscience.org/library/papers/6359081 | PubMed |
| 10 | 8324870 | Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8324870 | PubMed |
| 11 | 2225313 | Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2225313 | PubMed |
| 12 | 1206487 | Alkaloids of Vinca rosea L. (Catharanthus roseus G. Don) XXXVI: Isolation and characterization of new dimeric alkaloids. | J Pharm Sci | 1975 | https://conductscience.org/library/papers/1206487 | PubMed |
| 13 | 1851385 | A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. | Am J Clin Oncol | 1991 | https://conductscience.org/library/papers/1851385 | PubMed |
| 14 | 1444238 | Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review). | Anticancer Res | 1992 | https://conductscience.org/library/papers/1444238 | PubMed |
| 15 | 4761279 | Vinca alkaloids. XXXII. Microbiological conversions of vindoline, a major alkaloid from Vinca rosea L. | Helv Chim Acta | 1973 | https://conductscience.org/library/papers/4761279 | PubMed |
| 16 | 14070392 | THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. | Cancer Res | 1963 | https://conductscience.org/library/papers/14070392 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 7920369 | Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids. | Pharm World Sci | 1994 | https://conductscience.org/library/papers/7920369 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8306418
GET https://conductscience.org/api/papers/v1/8306418/authors